

## **SIGN SEMINAR**

Hosted by Prof Lam Kong Peng



## **Anish SURI (PhD)**

President & Chief Scientific Officer CUE Biopharma, Inc Boston, MA

## Immuno-STATs: TCR-selective Engagers for Precision Immunotherapy of Cancers

A major hurdle in cancer immunotherapy with cytokines such as IL-2 is lack of selectivity, which results in sub-optimal clinical benefit along with significant toxicities and tolerability challenges. Selective targeting of IL-2 to tumor-specific T cells over the vast majority of non-tumor-related TCR repertoire provides an opportunity to create a therapeutic index, hence maximizing potential benefit while limiting safety risks. To that end, we have engineered and clinically validated a novel class of T cell engagers, termed Immuno-STATs, that harness the TCR specificity of tumor-specific T cells, which allows us to deliver immune activation signals, such as IL-2, to the right T cells while avoiding the systemic activation of the broader immune system. We have dosed >100 patients with our lead clinical candidates, CUE-101 and CUE-102, that demonstrate single agent anti-tumor efficacy in late-stage metastatic cancer patients and significant increase in responses in combination with anti-PD-1 mAb in frontline metastatic cancer patients. Both clinical candidates demonstrate favorable tolerability with no evidence of serious IL-2-related toxicities that were noted in prior studies with IL-2 immunotherapy. These data provide compelling clinical validation and de-risking for the Immuno-STAT platform, which can be expanded to target many different cancers. Furthermore, an extension of the Immuno-STAT platform creates an attractive opportunity to develop a new class of therapeutics that can re-direct the protective anti-viral T cell repertoire to destroy cancers.



24 January 2024 (Wednesday) 11 AM - 12 PM (Singapore Time)

SIgN Seminar Room 8A Biomedical Grove, Immunos, #04-06 Singapore 138648 Seminar is open for all to attend.

Registration is not required.

